Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-31

Clinical Trial Update: Everolimus in Treating Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of everolimus for cutaneous T-cell lymphoma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Everolimus (everolimus)

Snippet

Sponsor: Adam Lerner | Conditions: Cutaneous T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2016-10-31